As 2023 draws to a close, the Tiefenbacher Group would like to share some of the year's highlights with you. This year we not only had our 60th anniversary to celebrate, but also many other great events:

In addition to several international generic launches we have successfully prepared the launch of the antihistamine Bilastine for a market entry as over-the-counter medicine in Germany. Furthermore we presented our innovative healthcare brand OYSTA in collaboration with OnDosis and inaugurated our new development block “Alfred” for highly potent drugs in Hyderabad, India.

Additionally we defined our sustainability goals for the future and started to implement them by installing solar panels at our site in Cyprus, replanting trees on building land in India, and setting up e-bike stations at our headquarters. Our social projects have not been neglected either, we have built a school in India, our employees have spent their social day in charitable institutions in Hamburg and our team has collected donations for charity.

This year we have been to numerous fairs and events to meet you in person and tell you about our latest product portfolio and how we make pharmaceuticals more affordable, more available, and better than before!

All in all we hope the year 2024 will be as successful and full of unique moments as the past one and we are looking forward to meeting you again in person all over the world!

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at or visit us on: